In regards to the two relatively young biotech stocks with monster potential discussed in today’s article, the author has the following to say: “…they have deeply compelling projects that aim to cure or fully mitigate a handful of different medical conditions that were once considered intractable. Both have demonstrated excellent progress so far, not to mention financial strength. It’ll take them some time to proceed with clinical trials and eventually pull through for shareholders, but when they do, the rewards could be enormous.” For more, CLICK HERE.
